Radiesse® Filler Press Releases
This section is designed to provide quick and easy access to the latest information and top news on RADIESSE dermal filler, the next generation, FDA-approved dermal filler that provides both immediate and long-lasting correction for the signs of HIV-Associated Facial Lipoatrophy – a common side effect from highly active antiretroviral therapy (HAART).
With its recent FDA-approval, RADIESSE treatment is now garnering positive coverage from print and broadcast media across the United States. To learn more about the success of RADIESSE dermal filler, please view the news reports and articles below.
Press Releases
FDA Approves RADIESSE Facial Filler for Two New Aesthetic Indications:
Long-Lasting Filler from BioForm Medical Approved for Treatment of Facial Wrinkles and Folds; and for the Correction of HIV-Associated Facial Wasting - December 27, 2006
FDA advisory panel recommends approval of RADIESSE for two facial aesthetic applications
General and Plastic Surgery Devices Advisory Panel Determines RADIESSE Safe and Effective in Correcting Facial Wrinkles and Folds and in the Restorative Treatment of HIV-Associated Facial Lipoatrophy - August 24, 2006
RADIESSE dermal filler receives facial aesthetics approval in Canada
Leading Canadian Distributor Canderm Pharma will Launch RADIESSE dermal filler to Plastic Surgeons and Dermatologists Seeking a Long-Lasting, Non-Permanent Filler for Facial Aesthetics - November 10, 2005
Landmark study of RADIESSE dermal filler finds 100% of patients report significant improvement in appearance of facial wasting at 12 months following treatment
BioForm Medical to File RADIESSE for Facial Soft Tissue Approval- September 28, 2005